Trial Profile
A 24-week randomised, double-blind, parallel-group, multi-centre, placebo controlled study to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when added to the therapy of patients with type 2 diabetes poorly controlled on metformin alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesaglitazar (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GALLANT-8
- Sponsors AstraZeneca
- 20 Mar 2006 New trial record.